| ||||||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||
Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter.
Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 111
Design Considerations for Evaluating the Impact of PEPFAR: Workshop Summary
Appendix A
Agenda
Design Considerations for Evaluating the Impact of PEPFAR
Monday, April 30–Tuesday, May 1, 2007
Institute of Medicine
Keck Building, 500 Fifth Street, N.W., Room 100, Washington, DC
Purpose: To discuss methodological, policy, and practical design considerations from the three main perspectives on accountability:
“Upward”—Congress
“Horizontal”—Global Partners/Coordination
“Downward”—Country Partners/Harmonization
The workshop was moderated by Ruth Levine, director of programs and senior fellow, Center for Global Development.
Portions of the workshop were webcast thanks to the Kaiser Family Foundation and are available at http://www.kaisernetwork.org/healthcast/ iom/30apr07.
Monday, April 30, 2007: Perspectives on Evaluation
9:00–9:10 a.m.
Welcome
Michele Orza, ScD
Study Director, PEPFAR Implementation Evaluation
Institute of Medicine (IOM)
OCR for page 112
Design Considerations for Evaluating the Impact of PEPFAR: Workshop Summary
9:10–9:15 a.m.
Introduction and Framing the Issues
Ruth Levine, PhD
Director of Programs and Senior Fellow
Center for Global Development
9:15–10:15 a.m.
Congressional Perspective
Purpose: To understand what Congress wants and needs to learn from impact evaluation; to discuss the evaluation language in The Leadership Act.
Savannah Lengsfelder, MA
Legislative Assistant
U.S. Senate Committee on Foreign Relations, Subcommittee on African Affairs
Christos Tsentas
Senior Legislative Assistant
Office of Representative Barbara Lee
David Gootnick, MD
Director, International Affairs and Trade
U.S. Government Accountability Office
Allen Moore, MBA
Senior Fellow, Global Health Council
Senior Associate, Center for Strategic and International Studies
Jim Sherry, MD, PhD (Discussant)
Subcommittee Member, IOM Committee for the Evaluation of PEPFAR Implementation
Professor and Chair, Department of Global Health
George Washington University
10:15–11:15 a.m.
PEPFAR Perspective
Purpose: To understand the U.S. Global AIDS Coordinator’s overall strategy for monitoring and evaluation, how impact evaluation fits into it, what program officials need and want to learn from impact evaluation, how they plan to coordinate and harmonize.
OCR for page 113
Design Considerations for Evaluating the Impact of PEPFAR: Workshop Summary
Tom Kenyon, MD, MPH
Principal Deputy U.S. Global AIDS Coordinator, Chief Medical Officer
Office of the U.S. Global AIDS Coordinator
Kathy Marconi, PhD, MS
Director of Monitoring, Evaluation, and Strategic Information
Office of the U.S. Global AIDS Coordinator
Shannon Hader, MD
Senior Scientific Advisor
Office of the U.S. Global AIDS Coordinator
11:15–11:30 a.m.
Break
11:30 a.m.–1:00 p.m.
Perspectives of Global Partners
Purpose: To learn the perspective of other donors with whom the United States should be coordinating with respect to monitoring and evaluation.
Paul R. De Lay, MD
Director, Monitoring and Evaluation
Joint United Nations Programme on HIV/AIDS
Jody Kusek, PhD
Lead Monitoring and Evaluation Specialist, Global HIV/AIDS Program
World Bank
Julia Compton, PhD
Senior Evaluation Manager, Evaluation Department
UK Department for International Development
Ambassador Jimmy Kolker (Discussant)
Deputy U.S. Global AIDS Coordinator
Office of the U.S. Global AIDS Coordinator
Jim Sherry, MD, PhD (Discussant)
Subcommittee Member, IOM Committee for the Evaluation of PEPFAR Implementation
Professor and Chair, Department of Global Health
George Washington University
1:00–1:30 p.m.
Lunch Break
OCR for page 114
Design Considerations for Evaluating the Impact of PEPFAR: Workshop Summary
1:30–2:15 p.m.
Luncheon Speaker and Discussion
“Monitoring and Evaluating Fairness in Scaling-Up ART”
Norman Daniels, PhD
Professor of Ethics and Population Health
Harvard School of Public Health
2:15–4:15 p.m.
Perspectives of Implementers and Country Partners
Purpose: To learn the perspective of various partners and stakeholders in the impact evaluation—the focus countries, program implementers, other programs with which the United States should be harmonized with respect to monitoring and evaluation, advocacy groups.
Agnes Binagwaho, MD
Executive Secretary
Rwanda National AIDS Control Commission
Jonathan Mwiindi
Director, Kijabe HIV/AIDS Relief Program, Kenya
HIV/AIDS Program Officer
Ecumenical Pharmaceutical Network
Nils Daulaire, MD, MPH
President and Chief Executive Officer
Global Health Council
Mary Lyn Field-Nguer, MSN, FNP
Director, Global HIV/AIDS Programs/Washington
John Snow, Inc.
Kent Glenzer, PhD
Director, Impact Measurement and Learning Team
CARE USA
Sara Pacqué-Margolis, MPH
Director, Monitoring and Evaluation
Elizabeth Glaser Pediatric AIDS Foundation
4:15–4:30 p.m.
Break
OCR for page 115
Design Considerations for Evaluating the Impact of PEPFAR: Workshop Summary
4:30–5:45 p.m.
Combined Panel
Moderated discussion with all panelists and audience.
Tuesday, May 1, 2007: Evaluation Design Challenges and Solutions
Purpose: To benefit from the experience of people who have evaluated or are currently evaluating programs that have major elements in common with the U.S. Global AIDS Initiative.
9:00–11:00 a.m.
Design Lessons Learned from Evaluating Donor Programs (Macro-, Meso-, Micro-Level)
Phillip Nieburg, MD, MPH (Moderator/Discussant)
Senior Associate and Co-Chair
Prevention Committee, HIV/AIDS Task Force
Center for Strategic and International Studies
Jaime Sepúlveda, MD, DrSc
Chair, IOM Committee for the Evaluation of PEPFAR Implementation
Visiting Professor and 2007 Presidential Chair
University of California–San Francisco
Martha Ainsworth, PhD
Lead Economist and Coordinator
Health and Education Evaluation Independent Evaluation Group
World Bank
Rachel Glennerster, PhD
Executive Director
Abdul Latif Jameel Poverty Action Laboratory
Julia Compton, PhD
Senior Evaluation Manager, Evaluation Department
UK Department for International Development
Kent Glenzer, PhD
Director, Impact Measurement and Learning Team
CARE USA
OCR for page 116
Design Considerations for Evaluating the Impact of PEPFAR: Workshop Summary
Stefano Bertozzi, MD, PhD
Member, IOM Committee for the Evaluation of PEPFAR Implementation
Member, The Technical Evaluation Reference Group–The Global Fund
Director, Division of Health Economics and Policy
National Institute of Public Health, Mexico
Jim Sherry, MD, PhD (Discussant)
Subcommittee Member, IOM Committee for the Evaluation of PEPFAR Implementation
Professor and Chair, Department of Global Health
School of Public Health and Health Services
George Washington University
11:00–11:15 a.m.
Break
11:15 a.m.–1:15 p.m.
Methodological Challenges (Meso-, Micro-Level)
Purpose: To discuss critical methodological issues and approaches for addressing them.
Focus: Evaluation of key AIDS-specific outcomes and impacts.
Paul R. De Lay, MD
Director, Monitoring and Evaluation
Joint United Nations Programme on HIV/AIDS
Theresa Diaz, MD, MPH
Branch Chief, Epidemiology and Strategic Information
Global AIDS Program, U.S. Centers for Disease Control and Prevention
Geoff Garnett, PhD
Member, IOM Committee for the Evaluation of PEPFAR Implementation
Professor of Microparasite Epidemiology
Imperial College
William L. Holzemer, RN, PhD, FAAN
Member, IOM Committee for the Evaluation of PEPFAR Implementation
Professor and Associate Dean, International Programs, School of Nursing
University of California–San Francisco
Rand Stoneburner, MD, MPH
Independent Consultant
OCR for page 117
Design Considerations for Evaluating the Impact of PEPFAR: Workshop Summary
Agnes Binagwaho, MD (Discussant)
Executive Secretary
Rwanda National AIDS Control Commission
Timothy Fowler, MA (Discussant)
Chief, Health Studies Branch, International Programs
U.S. Bureau of the Census
Rachel Glennerster, PhD
Executive Director
Abdul Latif Jameel Poverty Action Lab
Caroline Ryan, MD, MPH (Discussant)
Chief Technical Officer
Office of the U.S. Global AIDS Coordinator
1:15–2:00 p.m.
Lunch Break
2:00–4:00 p.m.
More Methodological Lessons/Challenges (Meso-, Micro-Level)
Purpose: To discuss critical methodological issues and approaches for addressing them.
Focus: Evaluation of key outcomes and impacts that are not AIDS specific.
Stefano Bertozzi, MD, PhD
Member, IOM Committee for the Evaluation of PEPFAR Implementation
Director, Division of Health Economics and Policy
National Institute of Public Health, Mexico
William L. Holzemer, RN, PhD, FAAN
Member, IOM Committee for the Evaluation of PEPFAR Implementation
Professor and Associate Dean, International Programs, School of Nursing
University of California–San Francisco
Carl Latkin, MS, PhD
Subcommittee Member, IOM Committee for the Evaluation of PEPFAR Implementation
Professor, Department of Health Policy and Management
Johns Hopkins School of Public Health
OCR for page 118
Design Considerations for Evaluating the Impact of PEPFAR: Workshop Summary
John Novak, PhD
Senior Monitoring and Evaluation Advisor, Office of HIV/AIDS
U.S. Agency for International Development
Jessica E. Price, PhD
Country Director, Rwanda
Family Health International
Julie Pulerwitz, ScD
Research Director, Horizons Program
Population Council, seconded from PATH
Martha Ainsworth, PhD (Discussant)
Lead Economist and Coordinator
Health and Education Evaluation Independent Evaluation Group
World Bank
Mary Lyn Field-Nguer, MSN, FNP (Discussant)
Director, Global HIV/AIDS Programs/Washington
John Snow, Inc.
Kent Glenzer, PhD (Discussant)
Director, Impact Measurement and Learning Team
CARE USA
Jonathan Mwiindi (Discussant)
Director, Kijabe HIV/AIDS Relief Program, Kenya
HIV/AIDS Program Officer
Ecumenical Pharmaceutical Network
Mead Over, PhD (Discussant)
Senior Fellow
Center for Global Development
4:00–4:15 p.m.
Break
4:15–5:45 p.m.
Combined Panel
Moderated discussion with all panelists and audience.
Summary of key issues and the way forward.
